Trials / Completed
CompletedNCT07220551
A Phase 1 Relative Bioavailability Study of UCB0022 Tablets in Healthy Participants
An Open-Label, Single-Center, Randomized, 2-Way Crossover Study to Evaluate the Relative Bioavailability and Safety of Two UCB0022 Tablet Formulations in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to estimate the relative bioavailability of UCB0022 Formulation 2 (Test) versus Formulation 1 (Reference) in healthy participants following single oral administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | UCB0022 | Participants will receive a single oral dose of UCB0022 tablet Formulation 1 and UCB0022 tablet Formulation 2 following a pre-specified sequence. |
Timeline
- Start date
- 2025-10-23
- Primary completion
- 2025-12-16
- Completion
- 2025-12-16
- First posted
- 2025-10-24
- Last updated
- 2026-01-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07220551. Inclusion in this directory is not an endorsement.